Influence of decision aids on patient preferences for anticoagulant therapy: a randomized trial

Holbrook, Anne; Labiris, Renée; Goldsmith, Charles H.; Ota, Kaede; Harb, Sandra; Sebaldt, Rolf J.
May 2007
CMAJ: Canadian Medical Association Journal;5/22/2007, Vol. 176 Issue 11, p1583
Academic Journal
Background: Decision aids have been shown to be useful in selected situations to assist patients in making treatment decisions. Important features such as the format of decision aids and their graphic presentation of data on benefits and harms of treatment options have not been well studied. Methods: In a randomized trial with a 3 × 2 factorial design, we investigated the effects of decision aid format (decision board, decision booklet with audiotape, or interactive computer program) and graphic presentation of data (pie graph or pictogram) on patients' comprehension and choices of 3 treatments for anticoagulation, identified initially as ‘treatment A’ (warfarin), ‘treatment B’ (acetylsalicylic acid) and ‘treatment C’ (no treatment). Patients aged 65 years or older without known atrial fibrillation and not currently taking warfarin were included. The effect of blinding to the treatment name was tested in a before-after comparison. The primary outcome was change in comprehension score, as assessed by the Atrial Fibrillation Information Questionnaire. Secondary outcomes were treatment choice, level of satisfaction with the decision aid, and decisional conflict. Results: Of 102 eligible patients, 98 completed the study. Comprehension scores (maximum score 10) increased by an absolute mean of 3.1 ( p< 0.01) after exposure to the decision aid regardless of the format or graphic presentation. Overall, 96% of the participants felt that the decision aid helped them make their treatment choice. Unblinding of the treatment name resulted in 36% of the participants changing their initial choice ( p< 0.001). Interpretation: The decision aid led to significant improvement in patients' knowledge regardless of the format or graphic representation of data. Revealing the name of the treatment options led to significant shifts in declared treatment preferences.


Related Articles

  • The safety and adequacy of antithrombotic therapy for atrial fibrillation: a regional cohort study. Burton, Chris; Isles, Chris; Norrie, John; Hanson, Ruth; Grubb, Elaine // British Journal of General Practice;Sep2006, Vol. 56 Issue 530, p697 

    Background Atrial fibrillation is a common problem in older people. The evidence base for the safety of warfarin and aspirin in atrial fibrillation is largely derived from selective research studies and secondary care. Further assessment of the safety of warfarin in older people with atrial...

  • Using decision aids to help patients navigate the "grey zone" of medical decision-making. O'Connor, Annette M. // CMAJ: Canadian Medical Association Journal Supplement;5/22/2007, Vol. 176 Issue 11, p1597 

    The author comments on the study "Influence of Decision Aids on Patient References for Anticoagulant Therapy: A Randomized Trial," by Anne Holbrook et al. According to her, the study asserts that the choice of anticoagulant therapy for atrial fibrillation is a grey zone decision for patients....

  • Clinical decision rules accurately predict stroke risk in atrial fibrillation. Gage, B. F.; Walraven, C.; Pearce, L. // Journal of Family Practice;Apr2005, Vol. 54 Issue 4, p309 

    This article reports that according to a study, clinical decision rules, especially the well- validated Stroke Prevention in Atrial Fibrillation score, can help identify which groups of patients with atrial fibrillation are likely and unlikely to benefit from anticoagulation. If the risk of...

  • Clopidogrel plus aspirin was inferior to oral anticoagulation for preventing vascular events in atriai fibrillation. Connofly, S. J.; Pogue, J.; Hart, R.; Sloan, Michael A. // Evidence Based Medicine;Dec2006, Vol. 11 Issue 6, p170 

    The article cites that clopidogrel plus aspirin was inferior to oral anticoagulation for preventing vascular events in patients with atrial fibrillation. Limitations of the study include the rates of stroke and other vascular events which were lower than in other trials. Some bias probably...

  • Long-Term Dabigatran Extension Study for Stroke Prevention in Treatment for Atrial Fibrillation. Rizzo, Toni // MD Conference Express;Dec2012, p25 

    The article discusses the Randomized Evaluation of Long-Term Anticoagulation Therapy (RELY-ABLE extension) trial by Stuart J. Connolly. The trial to describe the long-term efficacy and safety of ongoing dabigatran therapy after the RE-LY trial. It includes patients who had been randomized to...

  • Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective. Gustafsson, Claes; Asplund, Kjell; Britton, Mona; Norrving, Bo; Olsson, Bertil; Marke, Lars-Ake // BMJ: British Medical Journal (International Edition);12/12/92, Vol. 305 Issue 6867, p1457 

    Examines the potential effects of primary prevention with anticoagulants or aspirin on atrial fibrillation in Stockholm, Sweden. Dependence of the outcome on the rate of hemorrhagic complications; Occurrence of intra-cerebral hemorrhage; Effectivity of low intensity anticoagulant treatment.

  • Economic Evaluation of Enoxaparin for Anticoagulation in Early Cardioversion of Persisting Nonvalvular Atrial Fibrillation: A Statutory Health Insurance Perspective from Germany. Schädlich, Peter K.; Schmidt-Lucke, Caroline; Huppertz, Eduard; Lehmacher, Walter; Nixdorff, Uwe; Stellbrink, Christoph; Georg Brecht, Josef // American Journal of Cardiovascular Drugs;2007, Vol. 7 Issue 3, p199 

    OBJECTIVE: To estimate, from the perspective of Statutory Health Insurance (SHI, third-party payer) in Germany, the economic consequences of using the subcutaneous low-molecular-weight heparin (LMWH) enoxaparin instead of intravenous unfractionated heparin followed by oral phenprocoumon...

  • How to select a good candidate for left atrial appendage occlusion device: case report. Vujeva, Božo; Hadžibegović, Irzal; Starčević, Boris // Cardiologia Croatica;May/Jun2014, Vol. 9 Issue 5/6, p182 

    Atrial fibrillation is one of the most common arrhythmias and carries a great risk for cardioembolisation, with stroke and acute limb or mesenteric ischemia as one of the most severe consequences. Anticoagulation therapy is a gold standard therapy for embolic event protection, with new oral...

  • Shock Therapy Is Safe. Harrar, Sari // Prevention;Mar2003, Vol. 55 Issue 3, p176 

    Atrial fibrillation, the most common form of irregular heartbeat in adults, is caused by a glitch in the way the heart's natural pacemaker sends out electrical signals. The danger: Blood may pool in the heart and form clots, which can then get pushed to the brain, causing a stroke. Electric...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics